Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Company Deals

Tongling Bionic Raises Hundreds of Millions in Series B Financing for Cardiopulmonary Equipment Development

Fineline Cube Jul 19, 2022

Anhui Tongling Bionic Technology Co., Ltd, a Chinese developer of cardiopulmonary circulatory assist equipment, has...

Company Drug

Sesen Bio Terminates Vicineum Development After FDA Talks, Citing Phase III Costs

Fineline Cube Jul 19, 2022

Sesen Bio Inc. (NASDAQ: SESN) announced the termination of clinical development for Vicineum (VB4-845), its...

Company Medical Device

Huadong Medicine’s GFR Monitoring System Accepted by NMPA for Review

Fineline Cube Jul 19, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a glomerular...

Company Drug

Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis

Fineline Cube Jul 19, 2022

Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an...

Company Drug

Humanwell Healthcare’s RFUS-144 Wins NMPA Approval for Pruritus Clinical Study

Fineline Cube Jul 19, 2022

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Category 1 drug RFUS-144...

Company Deals

Brii Biosciences Partners with Huarun Medicine to Commercialize COVID-19 Antibody Cocktail in China

Fineline Cube Jul 19, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced a partnership with Huarun Medicine Business Group International...

Company Drug

Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China

Fineline Cube Jul 19, 2022

Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China’s homegrown innovative androgen receptor (AR)...

Company Deals

Chongqing Lummy Pharma Cancels YZY Biopharma Y400 Partnership, Secures Compensation

Fineline Cube Jul 19, 2022

China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership...

Drug

HutchMed Initiates Phase I Study of CD47 Monoclonal Antibody HMPL-A83 in China

Fineline Cube Jul 19, 2022

China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I clinical study...

Company Deals

Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China

Fineline Cube Jul 19, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in...

Company Deals

Fermion Secures Series B Financing to Advance AI-Driven Drug Development

Fineline Cube Jul 18, 2022

Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B...

Company Deals

Biotree Raises $14.8M in Series A Financing to Expand Multi-Omics Platform

Fineline Cube Jul 18, 2022

Shanghai-based multi-omics specialist Biotree has raised nearly RMB100 million ($14.8 million) in a Series A...

Company Drug

Kexing Pharmaceutical’s SHEN26 COVID-19 Drug Receives NMPA Approval for Clinical Trials

Fineline Cube Jul 18, 2022

China-based Kexing Pharmaceutical (SHA: 688136) announced that its oral small-molecule COVID-19 drug SHEN26, co-developed with...

Company Deals Digital

WeDoctor Partners with Jinan Innovation Zone to Launch Dual Healthcare Platform

Fineline Cube Jul 18, 2022

China-based WeDoctor Holdings Ltd, a Tencent-backed online medical service platform, has partnered with Jinan Innovation...

Company Drug

ImmuneOnco’s IMM2902 Receives FDA Fast-Track Designation for CD47/HER2 Targeting

Fineline Cube Jul 18, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that the U.S. Food and Drug Administration (FDA) has...

Policy / Regulatory

VBP Round 7 Drug Procurement Contract Awards Top Winners Revealed

Fineline Cube Jul 18, 2022

China’s 7th national Volume-Based Procurement (VBP) round concluded with winning bids for 60 drug products...

Company

Merck KGaA Launches Uptune Program in Asia, Offers Startups Up to €100,000

Fineline Cube Jul 18, 2022

Germany-based life sciences giant Merck KGaA has launched the Uptune program in Asia, offering up...

Company Drug

Pfizer Launches Cejemly in China for Stage III NSCLC, Expands Immunotherapy Reach

Fineline Cube Jul 18, 2022

Pfizer announced the commercial launch of Cejemly (sugemalimab) in China for Stage III non-small cell...

Company Deals

Sihuan Pharma to Sell Generic Drug Businesses, Shift Focus to Aesthetics and Biologics

Fineline Cube Jul 18, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced plans to divest a portion of...

Company Drug

Luye Pharma’s Lurbinectedin Receives Hainan Approval for SCLC Treatment

Fineline Cube Jul 18, 2022

China-based Luye Pharma Group (HKG: 2186) announced approval from the Hainan Medical Products Administration for...

Posts pagination

1 … 649 650 651 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.